Association between family functioning and psychotic transition in ultra-high risk adolescents and young adults.
FAD-60
adolescent
environment
family functioning
psychotic transition
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
03
2023
accepted:
24
05
2023
medline:
7
7
2023
pubmed:
7
7
2023
entrez:
7
7
2023
Statut:
epublish
Résumé
Psychotic transition (PT) is a crucial stage in schizophrenia. The Comprehensive Assessment of At-Risk Mental States (CAARMS) scale can be used to identify individuals at ultra-high risk (UHR) for psychosis and to evaluate their risk of PT. Many environmental and genetic factors have been identified as contributing to the development and decompensation of schizophrenia. This study aimed to determine if the quality of family functioning is associated with PT risk in UHR individuals aged between 11 and 25 years after 1 year of follow-up. From January to November 2017, 45 patients aged 12 to 25 consulting for psychiatric reasons were included. Twenty-six were classified as UHR of PT at the CAARMS. Family functioning was assessed by the Family Assessment Device-Global Functioning (FAD-GF). Thirty-seven of these patients (30% men, mean age 16 ± 2.5) were reassessed at 8-14 months of recruitment. Survival analysis was used to examine the impact of family functioning on PT risk. A total of 40% of UHR patients were classified as psychotic at reassessment. Survival analysis showed that better family functioning is a significant protective factor for PT in this population. This result suggests that the global family functioning has an impact at 1 year on the risk of PT in the population of adolescents and young adults who consult the hospital for psychiatric reasons. A family intervention may be effective in reducing PT risk in this population and should be considered as a potential therapeutic option.
Sections du résumé
Background
UNASSIGNED
Psychotic transition (PT) is a crucial stage in schizophrenia. The Comprehensive Assessment of At-Risk Mental States (CAARMS) scale can be used to identify individuals at ultra-high risk (UHR) for psychosis and to evaluate their risk of PT. Many environmental and genetic factors have been identified as contributing to the development and decompensation of schizophrenia. This study aimed to determine if the quality of family functioning is associated with PT risk in UHR individuals aged between 11 and 25 years after 1 year of follow-up.
Methods
UNASSIGNED
From January to November 2017, 45 patients aged 12 to 25 consulting for psychiatric reasons were included. Twenty-six were classified as UHR of PT at the CAARMS. Family functioning was assessed by the Family Assessment Device-Global Functioning (FAD-GF). Thirty-seven of these patients (30% men, mean age 16 ± 2.5) were reassessed at 8-14 months of recruitment. Survival analysis was used to examine the impact of family functioning on PT risk.
Results
UNASSIGNED
A total of 40% of UHR patients were classified as psychotic at reassessment. Survival analysis showed that better family functioning is a significant protective factor for PT in this population.
Discussion
UNASSIGNED
This result suggests that the global family functioning has an impact at 1 year on the risk of PT in the population of adolescents and young adults who consult the hospital for psychiatric reasons. A family intervention may be effective in reducing PT risk in this population and should be considered as a potential therapeutic option.
Identifiants
pubmed: 37415693
doi: 10.3389/fpsyt.2023.1177311
pmc: PMC10320389
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1177311Informations de copyright
Copyright © 2023 Adrien, Liewig, Diot, Ferreri, Mouchabac, Dubertret and Bourgin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Psychiatry Res. 2020 Jun;288:112968
pubmed: 32320861
Schizophr Bull. 2016 Jul;42(4):926-32
pubmed: 26757754
Clin Child Psychol Psychiatry. 2022 Jul;27(3):630-643
pubmed: 35200051
Nord J Psychiatry. 2003;57(3):209-14
pubmed: 12775296
Child Adolesc Psychiatr Clin N Am. 2017 Apr;26(2):341-366
pubmed: 28314460
Schizophr Res. 2020 Jan;215:277-283
pubmed: 31615738
JAMA Psychiatry. 2013 Jan;70(1):107-20
pubmed: 23165428
Schizophr Res. 2009 Feb;107(2-3):198-205
pubmed: 18996681
Fam Process. 1994 Mar;33(1):53-69
pubmed: 8039568
Fam Syst Health. 2020 Jun;38(2):151-161
pubmed: 32525350
Soc Psychiatry Psychiatr Epidemiol. 2014 Jul;49(7):1023-36
pubmed: 24407976
Clin Child Psychol Psychiatry. 2019 Oct;24(4):809-820
pubmed: 31094226
Acta Psychiatr Scand. 2020 May;141(5):410-420
pubmed: 31903545
Eur J Psychotraumatol. 2013 Sep 12;4:
pubmed: 24044071
Can J Psychiatry. 2012 Sep;57(9):570-7
pubmed: 23073035
Ann Gen Psychiatry. 2010 May 07;9:20
pubmed: 20459646
Encephale. 2014 Dec;40(6):447-56
pubmed: 25127895
Can J Psychiatry. 1994 Feb;39(1):49-54
pubmed: 8193998
Psychiatry Res. 2017 Jan;247:345-351
pubmed: 27987484
Fam Process. 2015 Mar;54(1):94-115
pubmed: 25154959
Evid Based Ment Health. 2015 May;18(2):59
pubmed: 25802364
Epidemiol Rev. 2008;30:67-76
pubmed: 18480098
Schizophr Res. 1994 Oct;13(3):195-207
pubmed: 7841132
JAMA Psychiatry. 2021 Sep 1;78(9):970-978
pubmed: 34259821
Eat Disord. 2021 Jul-Aug;29(4):327-343
pubmed: 31414973
Eur Psychiatry. 2017 Feb;40:65-75
pubmed: 27992836
Eur Psychiatry. 2018 Sep;53:37-45
pubmed: 29870894
JAMA Psychiatry. 2020 Mar 1;77(3):311-320
pubmed: 31746950
Front Psychiatry. 2019 Oct 24;10:774
pubmed: 31708822
Schizophr Res. 2019 Feb;204:337-342
pubmed: 30205908
Dialogues Clin Neurosci. 2006;8(1):137-42
pubmed: 16640125
Lancet Public Health. 2019 May;4(5):e229-e244
pubmed: 31054641
J Affect Disord. 2022 Dec 15;319:562-569
pubmed: 36167245
Am J Psychiatry. 2016 Jan;173(1):44-52
pubmed: 26472628
Psychiatry Res. 2019 Mar;273:192-196
pubmed: 30654304
Neurosci Lett. 1980 Dec;20(3):379-82
pubmed: 6108541
Fam Process. 1988 Mar;27(1):97-104
pubmed: 3360100
Harv Rev Psychiatry. 2013 Nov-Dec;21(6):281-95
pubmed: 24201820
Psychol Med. 2013 Jul;43(7):1365-76
pubmed: 23084507
Fam Process. 2015 Mar;54(1):82-93
pubmed: 24920469
PLoS One. 2015 Sep 22;10(9):e0138361
pubmed: 26394221
Eur Psychiatry. 2018 Mar;49:62-68
pubmed: 29413807
Early Interv Psychiatry. 2008 Nov;2(4):268-76
pubmed: 21352160
Psychoneuroendocrinology. 2015 Jul;57:26-36
pubmed: 25880698
Arch Gen Psychiatry. 1999 Feb;56(2):162-8
pubmed: 10025441
Drug Alcohol Rev. 2021 Nov;40(7):1334-1339
pubmed: 33855757
J Abnorm Psychol. 2021 Aug;130(6):587-593
pubmed: 34553954
Ann Med Psychol (Paris). 1981 Apr;139(4):446-53
pubmed: 7305179
Schizophr Res. 2015 Oct;168(1-2):56-61
pubmed: 26213342